Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Prices IPO at $15 a Share


Dicerna Pharmaceuticals this week priced its initial public offering of 6 million shares of its common stock at $15 a share — higher than the $13 to $15 range it had previously projected.

As a result, the IPO is valued at $90 million, significantly more than the $69 million Dicerna originally said it hoped to raise in the offering. That number could increase should the underwriters of the offering exercise their option to buy another 900,000 shares.

Jefferies, Leerink Partners, and Stifel, Nicolaus & Company are the joint book-running managers of the IPO. Robert W. Baird & Co. is co-lead manager.

Dicerna's stock will now trade under the symbol "DRNA" on the Nasdaq.

The public offering, which marks only the second time an RNAi drug developer has completed an IPO, is widely seen as indication that Wall Street is warming up to RNAi after the field hit a rough patch in 2010/2011 when Pfizer and Roche dropped their in-house nucleic acid drug-development efforts.

Even more compelling is that Dicerna completed the IPO even as a company without a single drug in the clinic and, as it noted in a recent regulatory filing, without exclusive ownership of its core RNAi drug technology.

Dicerna aims to used the proceeds of the IPO, which follows a $60 million private Series C round in August, to advance its internal pipeline, which includes the Myc-targeting hepatocellular carcinoma treatment DCR-M1711 — set to reach phase I testing this year — and earlier-stage therapies for primary hyperoxaluria 1 and other rare, genetic diseases.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.